Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
ApexOnco Front Page
Recent articles
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
The group eyes a broader use than Immunocore’s Kimmtrak.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.